May 14th 2024
During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Dara-RVd Reduces Risk of Progression or Death in Transplant-Eligible NDMM
August 28th 2022The combination of daratumumab plus lenalidomide, bortezomib, and dexamethasone continued to show superior efficacy in patients with newly diagnosed multiple myeloma based on the GRIFFIN trial's final analysis reported at the 19th International Myeloma Society annual meeting.
Read More
Carfilzomib Plus Lenalidomide/Dexamethasone After Transplant Extends PFS Over Lenalidomide in MM
August 26th 2022Data presented at the 19th International Myeloma Society Annual Meeting show that carfilzomib plus lenalidomide and dexamethasone after transplant prolongs progression-free survival compared with lenalidomide alone in patients with myeloma.
Read More
Daratumumab Plus Lenalidomide/Dexamethasone Prolong OS When Administered Long-Term in Myeloma
August 26th 2022Patients with treatment-naive myeloma treated with humanized IgGx CD38-targeted monoclonal antibody daratumumab in combination with lenalidomide and dexamethasone for at least 18 months had a overall survival benefit in the phase 3 MAIA study.
Read More
Isa-Kd Maintains Long-Term PFS Benefit in Relapsed Multiple Myeloma
August 26th 2022Updated analysis of the IKEMA trial showed the combination of isatuximab, carfilzomib, and dexamethasone to elicit superior progression-free survival vs carfilzomib and dexamethasone alone in patients with multiple myeloma.
Read More
Lenalidomide Triplet plus ASCT Significantly Improves PFS in Multiple Myeloma
August 26th 2022Findings from the phase 3 DETERMINATION trial show lenalidomide plus bortezomib, dexamethasone, and autologous stem cell transplantation to improve progression-free survival in patients with multiple myeloma.
Read More
Talquetamab/Daratumumab Combination Appears Safe in Patients With Anti-CD38–Refractory Myeloma
August 18th 2022The combination of talquetamab and daratumumab has the potential to demonstrate synergistic clinical activity, and preclinical studies have shown that the addition of daratumumab enhanced talquetamabmediated lysis of multiple myeloma cells.
Read More
Ide-cel Prolongs Progression-Free Survival in Heavily Pretreated R/R Multiple Myeloma
August 10th 2022Results from the interim analysis of phase 3 KarMMa-3 study indicate improvement in progression-free survival with idecabtagene vicleucel compared with standard combination regimens, as well as better responses.
Read More
Triplet Therapy Plus Transplantation Prolongs PFS in Multiple Myeloma
August 8th 2022With a median progression-free survival of 46.2 months in the RVD-alone group and 67.5 months in the transplantation group, lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplantation extends overall survival in patients with newly diagnosed multiple myeloma.
Read More
Treating Multiple Myeloma Following Quadruplet Induction Therapy and ASCT
August 1st 2022During a Targeted Oncology live virtual event, Caitlin Costello, MD, discussed treatment of a patient who previously received systemic therapy and autologous stem cell transplant for multiple myeloma. This is the second of 2 articles based on this event.
Read More
Anderson Reviews Data for Belantamab Mafodotin as Later-Line Therapy for Multiple Myeloma
July 18th 2022During a Targeted Oncology case-based roundtable event, Larry D. Anderson, MD, PhD, discussed the results of the DREAMM-2 trial and management of belantamab mafodotin for patients with multiple myeloma.
Read More